Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Growth in 2025?

The market size for drugs treating asthma and chronic obstructive pulmonary disease (copd) has seen robust growth over the past few years. The prediction is an increase from $32.52 billion in 2024 to $35.66 billion in 2025, with a compound annual growth rate (CAGR) of 9.6%. This growth during the previous period can be credited to factors such as escalating air pollution levels, increased rates of tobacco smoking, a greater understanding of respiratory diseases, increased use of corticosteroids and bronchodilators, and growing healthcare spending.

What Is the Forecast for the Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Size Through 2029?

The market size for asthma and chronic obstructive pulmonary disease (copd) medication is anticipated to witness significant expansion in the ensuing years. The market value is projected to reach $50.99 billion in 2029, showcasing a compound annual growth rate (CAGR) of 9.4%. Factors contributing to this growth in the predicted period include the expanding demand for personalized medication, wider acceptance of biologics and sophisticated therapies, the growing prevalence of allergies stemming from the environment, an increase in clinical trials and their subsequent approvals, as well as the escalating load of non-communicable ailments. Prominent trends during the forecast period entail smart inhalers enabled by technology, the development of dual-functioning bronchodilators, the incorporation of electronic health records (EHR) into drug data, the innovation of biopharmaceutical molecules, and the use of machine learning in drug discovery.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp

What are the Key Market Players in Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market and How They’re Evolving?

Major companies operating in the asthma and chronic obstructive pulmonary disease (COPD) drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. (Roche), Merck & Co. Inc., Sanofi, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc (GSK), Eli Lilly and Company, Amgen, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma, AptarGroup, Chiesi Farmaceutici S.p.A., Dr. Reddy’s Laboratories, Cipla Inc., Lupin Limited, Zydus Cadila, Glenmark Pharmaceuticals, Vectura Group, Aurobindo Pharma

What Are the Primary Growth Drivers in the Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

The rising incidence of smoking is predicted to fuel the expansion of the asthma and COPD drugs market in the future. Smoking, the act of consuming tobacco inhaled as smoke, can result in severe health problems like lung cancer and heart disease. The surge in smoking prevalence is predominantly triggered by societal influence. Peer pressure, cultural standards, and social atmospheres encourage people to initiate and maintain the habit. Drugs for asthma and chronic obstructive pulmonary disease (COPD) can lessen the pulmonary damage caused by smoking. They work by decreasing inflammation, easing the muscles in the airways and enhancing airflow, easing symptoms and boosting lung functionality. For example, a 2024 study on youth smoking trends by the European Respiratory Society’s (ERS), a not-for-profit organization based in Switzerland, reported a significant spike in the number of smokers, escalating from 22.5% of participants in 2022 to 40.1% in 2024. Consequently, the escalating incidence of smoking is bolstering the asthma and COPD drugs market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24472&type=smp

What Are the Leading Segments in the Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry?

The asthma and chronic obstructive pulmonary disease (COPD) drugs market covered in this report is segmented –

1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers

2) By Route Of Administration: Inhalation, Oral, Injection, Nasal, Other Route Of Administrations

3) By Patient Group: Adult, Pediatric, Geriatric

4) By Application: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Hypertension

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments

1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines

2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids

3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid

4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors

What Are the Key Market Trends in the Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry?

Leading businesses in the asthma and COPD medication market are concentrating their efforts on creating new formulations, such as fixed-dose combination (FDC) drugs, to enhance patient adherence and the effectiveness of treatment. An FDC medication is a single dose form that includes two or more active ingredients, which assists in the management of asthma and COPD by incorporating bronchodilators and anti-inflammatories, leading to better symptom control and patient adherence. For instance, Glenmark Pharmaceuticals Limited, a pharmaceutical company based in India, introduced Indamet, an innovative FDC medication that combines Indacaterol, a long-acting beta-agonist (LABA), and Mometasone Furoate, an inhaled corticosteroid (ICS), for treating uncontrolled asthma in June 2022. The Drug Controller General of India (DCGI) gave approval for Indamet, marking it as the first FDC of its kind introduced in India, and it is available in Indacaterol 150 mcg combined with Mometasone in three strengths – 80 mcg, 160 mcg, or 320 mcg, to be taken once daily. The purpose of this formulation is to improve lung function, lessen symptom prevalence, decrease exacerbation frequency, and boost treatment adherence in adult and adolescent patients who are 12 years old and above.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/asthma-and-chronic-obstructive-pulmonary-disease-copd-drugs-global-market-report

What Is the Regional Outlook for the Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?

North America was the largest region in the asthma and COPD drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (COPD) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24472

This Report Delivers Insight On:

1. How big is the asthma and chronic obstructive pulmonary disease (copd) drugs market, and how is it changing globally?

2. Who are the major companies in the asthma and chronic obstructive pulmonary disease (copd) drugs market, and how are they performing?

3. What are the key opportunities and risks in the asthma and chronic obstructive pulmonary disease (copd) drugs market right now?

4. Which products or customer segments are growing the most in the asthma and chronic obstructive pulmonary disease (copd) drugs market?

5. What factors are helping or slowing down the growth of the asthma and chronic obstructive pulmonary disease (copd) drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model